In particular, the MYBL1 fusion transcript detected was the only putative oncogenic driver in this case, over all platforms including WES, and was subsequently reported as a recurrent driver in a subset of pediatric infiltrating gliomas.31 Moreover, the alteration is now entity-defining according to new WHO criteria.13 In contrast, a fusion such as the IRAK1BP1-KPNA5 has not been detected by our group in any additional cases and has not been reported previously, thus its functional significance remains unknown and further experiments would be required to characterize its oncogenic potential. The gene discussed is MYBL1; the disease is central nervous system cancer.